Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Abstract PO4-17-12: Early adherence to adjuvant abemaciclib: Data from the Belgian Medical Need Program

Maxime Van Houdt, Marc Michaux, Sevilay Altintas, Ahmad Awada, Jean-Luc Canon, Hannelore Denys, François Duhoux, Guy Jerusalem, Jeroen Mebis, Rosanne Janssens, Isabelle Huys, Barbier Liese, Charlotte Verbeke, Sileny Han, Hans Wildiers, Patrick Neven

Cancer Res (2024) 84 (9_Supplement): PO4-17-12.

https://doi.org/10.1158/1538-7445.SABCS23-PO4-17-12

Published: 02 May 2024

View article titled, Abstract PO4-17-12: Early adherence to adjuvant abemaciclib: Data from the Belgian Medical Need Program

Journal Articles

Abstract 4926: Alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2+, PIK3CA-mutant advanced breast cancer: EPIK-B2 Study Part 1 safety and efficacy results

Sara A. Hurvitz, François-Clement Bidard, Wei Li, Xichun Hu, Sonia Pernas, Joseph Thaddeus Beck, Mario Campone, Kevin Punie, Michelle Miller, Mathilde Kaper, Yu Han, Farhat Ghaznawi, Guy Jerusalem

Cancer Res (2023) 83 (7_Supplement): 4926.

https://doi.org/10.1158/1538-7445.AM2023-4926

Published: 04 April 2023

View article titled, Abstract 4926: Alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2+, <em>PIK3CA</em>-mutant advanced breast cancer: EPIK-B2 Study Part 1 safety and efficacy results

Journal Articles

Abstract P3-05-28: Impact of increased adiposity on extended aromatase inhibitor treatment in postmenopausal patients with estrogen receptor positive (ER+) breast cancer: a retrospective analysis of the SOLE trial

Edoardo Isnaldi, François Richard, Giuseppe Marano, Patrizia Boracchi, Marion Maetens, Giuseppe Floris, Guy Jerusalem, Andrea Gombos, Alastair M. Thompson, Erika Hitre, Stefan Aebi, Marco Colleoni, Patrizia Dell’Orto, Roswitha Kammler, Patrick Neven, Giuseppe Viale, Meredith Regan, Elia Biganzoli, Christine Desmedt

Cancer Res (2023) 83 (5_Supplement): P3-05-28.

https://doi.org/10.1158/1538-7445.SABCS22-P3-05-28

Published: 01 March 2023

View article titled, Abstract P3-05-28: Impact of increased adiposity on extended aromatase inhibitor treatment in postmenopausal patients with estrogen receptor positive (ER+) breast cancer: a retrospective analysis of the SOLE trial

Journal Articles

Abstract P4-01-29: Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2- metastatic breast cancer

Yentl Lambrechts, Sigrid Hatse, Cindy Kenis, Lore Decoster, Evandro de Azambuja, Guy Jerusalem, Patrick Neven, Lissandra Dal Lago, Hannelore Denys, Peter Vuylsteke, Frank Cornelis, Kevin Punie, Giuseppe Floris, Christine Desmedt, Annouschka Laenen, Noam Pondé, Hans Wildiers

Cancer Res (2023) 83 (5_Supplement): P4-01-29.

https://doi.org/10.1158/1538-7445.SABCS22-P4-01-29

Published: 01 March 2023

View article titled, Abstract P4-01-29: Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2- metastatic breast cancer

Journal Articles

Abstract OT2-16-02: Open-label, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer: DESTINY-Breast12

Nancy U. Lin, Eva Ciruelos, Guy Jerusalem, Volkmar Müller, Naoki Niikura, Giuseppe Viale, Emma Oscroft, Shawn Anand, Manoj Prahladan, Nadia Harbeck

Cancer Res (2023) 83 (5_Supplement): OT2-16-02.

https://doi.org/10.1158/1538-7445.SABCS22-OT2-16-02

Published: 01 March 2023

View article titled, Abstract OT2-16-02: Open-label, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer: DESTINY-Breast12

Journal Articles

Editor's Note: EGFR Activation and Signaling in Cancer Cells Are Enhanced by the Membrane-Bound Metalloprotease MT4-MMP

Alexandra Paye, Alice Truong, Cassandre Yip, Jonathan Cimino, Silvia Blacher, Carine Munaut, Didier Cataldo, Jean Michel Foidart, Erik Maquoi, Joelle Collignon, Philippe Delvenne, Guy Jerusalem, Agnes Noèl, Nor Eddine Sounni

Cancer Res (2022) 82 (4): 734.

https://doi.org/10.1158/0008-5472.CAN-21-4292

Published: 15 February 2022

View article titled, Editor's Note: EGFR Activation and Signaling in Cancer Cells Are Enhanced by the Membrane-Bound Metalloprotease MT4-MMP

Journal Articles

Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Cancer Res (2022) 82 (4_Supplement): OT1-02-02.

https://doi.org/10.1158/1538-7445.SABCS21-OT1-02-02

Published: 15 February 2022

View article titled, Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Journal Articles

Abstract OT2-26-01: Open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC): DESTINY-Breast12

Nancy U Lin, Eva Ciruelos, Guy Jerusalem, Volkmar Müller, Naoki Niikura, Giuseppe Viale, Emma Oscroft, Shawn Anand, Graham Walker, Nadia Harbeck

Cancer Res (2022) 82 (4_Supplement): OT2-26-01.

https://doi.org/10.1158/1538-7445.SABCS21-OT2-26-01

Published: 15 February 2022

View article titled, Abstract OT2-26-01: Open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC): DESTINY-Breast12

Journal Articles

Abstract OT-37-01: Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18

Michael Schwitter, Khalil Zaman, Guy Jerusalem, Marina Cazzaniga, Richard Greil, Ursula Strub Ursula, Andreas Mueller, Catrina Uhlmann Nussbaum, Agnès Auteri, Karin Rothgiesser, Daniel Dietrich, Thomas Ruhstaller

Cancer Res (2021) 81 (4_Supplement): OT-37-01.

https://doi.org/10.1158/1538-7445.SABCS20-OT-37-01

Published: 15 February 2021

View article titled, Abstract OT-37-01: Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18

Journal Articles

Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial

Cancer Res (2021) 81 (4_Supplement): PS5-05.

https://doi.org/10.1158/1538-7445.SABCS20-PS5-05

Published: 15 February 2021

View article titled, Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial

Journal Articles

Abstract PS10-05: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial

Janice Lu, Paul Cottu, Miguel Martín, Claudio Zamagni, Aleix Prat, Stephen Chia, Guy Jerusalem, Senthil Rajappa, Constanta Timcheva, Lyudmila Zhukova, Katie Zhou, Jiwen Wu, Lakshmi Menon-Singh, Michelino De Laurentiis

Cancer Res (2021) 81 (4_Supplement): PS10-05.

https://doi.org/10.1158/1538-7445.SABCS20-PS10-05

Published: 15 February 2021

View article titled, Abstract PS10-05: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial

Journal Articles

Abstract PS17-01: A metabolomic signature as screening method for breast cancer diagnosis

Concetta Elisa Onesti, François Boemer, Claire Josse, Ahmed Debit, Christophe Poulet, Vincent Bours, Guy Jerusalem

Cancer Res (2021) 81 (4_Supplement): PS17-01.

https://doi.org/10.1158/1538-7445.SABCS20-PS17-01

Published: 15 February 2021

View article titled, Abstract PS17-01: A metabolomic signature as screening method for breast cancer diagnosis

Journal Articles

Abstract 785: Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study

Erika P. Hamilton, Javier Cortes, Guy Jerusalem, Peter A. Kaufman, Ozgur Ozyilkan, Roberto Hegg, Lacey M. Litchfield, Hong Wang, Hillary T. Graham, Sameera R. Wijayawardana, Valerie M. Jansen, Miguel Martin

Cancer Res (2020) 80 (16_Supplement): 785.

https://doi.org/10.1158/1538-7445.AM2020-785

Published: 15 August 2020

View article titled, Abstract 785: Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study

Journal Articles

Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results

Hope S. Rugo, J. Thad Beck, Guy Jerusalem, Hans Wildiers, Peter Kabos, Michael Chisamore, Rhian McNaughton, Yanyun Chen, Anwar Hossain, Sara M. Tolaney

Cancer Res (2020) 80 (16_Supplement): CT108.

https://doi.org/10.1158/1538-7445.AM2020-CT108

Published: 15 August 2020

View article titled, Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results

Journal Articles

Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors

Cancer Res (2020) 80 (16_Supplement): CT301.

https://doi.org/10.1158/1538-7445.AM2020-CT301

Published: 15 August 2020

View article titled, Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors

Journal Articles

Abstract P5-12-01: SOLE (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC): Final analysis and sole estrogen substudy (SOLE-EST)

Cancer Res (2020) 80 (4_Supplement): P5-12-01.

https://doi.org/10.1158/1538-7445.SABCS19-P5-12-01

Published: 15 February 2020

View article titled, Abstract P5-12-01: SOLE (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC): Final analysis and sole estrogen substudy (SOLE-EST)

Journal Articles

Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer

Cancer Res (2020) 80 (4_Supplement): GS1-04.

https://doi.org/10.1158/1538-7445.SABCS19-GS1-04

Published: 15 February 2020

View article titled, Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer

Journal Articles

Abstract OT2-04-02: CheckMate 7A8: A phase 2 trial of nivolumab + abemaciclib or palbociclib + anastrozole in postmenopausal women with ER+, HER2−primary breast cancer

Sara Tolaney, Guy Jerusalem, Roberto Salgado, Xiaochun Liu, Tian Chen, Hongxia Zhang, Mustimbo Roberts, Dimitrios Zardavas, Aleix Prat

Cancer Res (2020) 80 (4_Supplement): OT2-04-02.

https://doi.org/10.1158/1538-7445.SABCS19-OT2-04-02

Published: 15 February 2020

View article titled, Abstract OT2-04-02: CheckMate 7A8: A phase 2 trial of nivolumab + abemaciclib or palbociclib + anastrozole in postmenopausal women with ER+, HER2−primary breast cancer

Journal Articles

Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial

Karen Kelly, Manish Patel, Jeffrey R. Infante, Nicholas Iannotti, Petros Nikolinakos, Joseph Leach, Ding Wang, Jason Chandler, Guy Jerusalem, Jayne Gurtler, Henrik-Tobias Arkenau, Marcis Bajars, Anja von Heydebreck, Isabell Speit, Christopher R. Heery, James L. Gulley

Cancer Res (2016) 76 (14_Supplement): CT132.

https://doi.org/10.1158/1538-7445.AM2016-CT132

Published: 15 July 2016

View article titled, Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial

Journal Articles

Tissue Factor Induced by Epithelial–Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells

Morgane Bourcy, Meggy Suarez-Carmona, Justine Lambert, Marie-Emilie Francart, Hélène Schroeder, Céline Delierneux, Nicolas Skrypek, Erik W. Thompson, Guy Jérusalem, Geert Berx, Marc Thiry, Silvia Blacher, Brett G. Hollier, Agnès Noël, Cécile Oury, Myriam Polette, Christine Gilles

Cancer Res (2016) 76 (14): 4270–4282.

https://doi.org/10.1158/0008-5472.CAN-15-2263

Published: 14 July 2016

View article titled, Tissue Factor Induced by Epithelial–Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells

Includes: Supplementary data

NARROW

Abstract PO4-17-12: Early adherence to adjuvant abemaciclib: Data from the Belgian Medical Need Program

Abstract 4926: Alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2+, PIK3CA-mutant advanced breast cancer: EPIK-B2 Study Part 1 safety and efficacy results

Abstract P3-05-28: Impact of increased adiposity on extended aromatase inhibitor treatment in postmenopausal patients with estrogen receptor positive (ER+) breast cancer: a retrospective analysis of the SOLE trial

Abstract P4-01-29: Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2- metastatic breast cancer

Abstract OT2-16-02: Open-label, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer: DESTINY-Breast12

Editor's Note: EGFR Activation and Signaling in Cancer Cells Are Enhanced by the Membrane-Bound Metalloprotease MT4-MMP

Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Abstract OT-37-01: Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18

Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial

Abstract PS10-05: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial

Abstract PS17-01: A metabolomic signature as screening method for breast cancer diagnosis

Abstract 785: Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study

Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results

Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors

Abstract OT2-04-02: CheckMate 7A8: A phase 2 trial of nivolumab + abemaciclib or palbociclib + anastrozole in postmenopausal women with ER+, HER2−primary breast cancer

Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial

Tissue Factor Induced by Epithelial–Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only